( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



M. Kanaka Prasada Rao* and V.V.V. Satyanarayana


Background: Trichomoniasis is a common sexually transmitted disease (STD) among high risk populations. Trichomoniasis is a sexually transmitted infection (STI) usually associated to vaginitis, urethritis, cervicitis and pelvic inflammatory disease, which can cause infertility. Objective: The aim of this retrospective longitudinal study was to determine the efficacy of Metronidazole 2gm stat. in Trichomoniasis in High-Risk female patients attended to RIMS, Srikakulam, Andhrapradesh. Study Design: A cohort of 300 people who attended the STI Clinic and Gynaecology OP in this province was retrospectively analyzed from September 2011 up to April 2014. Material and Methods: Three hundred women (300 from Obstetrics and Gynecology Outpatient Department and STD OPD) patients attending Government General Hospital, attached to the Rajiv Gandhi Institute of Medical Sciences(RIMS), Srikakulam, Andhra Pradesh, India between September 2011 to April 2014, were enrolled in the present study after taking their due consent, with symptoms of trichomoniasis. Their age, occupation, clinical, obstetrical history, and relevant per speculum findings were recorded on a preplanned proforma. Both vaginal swabs and urine samples were subjected to wet smear examination and culture for detection of parasites. Result: With 2 gm Metronidazole as a single dose, we did not get any treatment failures in our study. Summary: Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. Conclusion: With 2 gm Metronidazole as a single dose, we did not get any treatment failure in our study.Our patients tolerated the dose very well. So, we recommend Metronidazole 2 gm stat. dose for the patients with Trichomoniasis.

Keywords: Metronidazole, Trichomonas vaginalis, High risk groups.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 April 2024 Issue has been Published, Kindly check it on


    APRIL 2024 issue has been successfully launched on APRIL 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia